Senti Biosciences (NASDAQ:SNTI) Releases Quarterly Earnings Results, Beats Expectations By $0.22 EPS

Senti Biosciences (NASDAQ:SNTI) issued its earnings results on Thursday. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.22, FiscalAI reports. The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.02 million.

Senti Biosciences Trading Up 8.0%

Shares of NASDAQ:SNTI opened at $1.04 on Friday. Senti Biosciences has a 1 year low of $0.77 and a 1 year high of $3.88. The business has a fifty day simple moving average of $0.95 and a 200 day simple moving average of $1.22. The firm has a market cap of $32.39 million, a price-to-earnings ratio of -0.33 and a beta of 2.09.

Institutional Trading of Senti Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of SNTI. Jane Street Group LLC purchased a new stake in shares of Senti Biosciences during the fourth quarter worth $40,000. Virtu Financial LLC purchased a new stake in shares of Senti Biosciences during the fourth quarter worth $46,000. Citadel Advisors LLC purchased a new stake in shares of Senti Biosciences during the third quarter worth $117,000. Geode Capital Management LLC raised its holdings in shares of Senti Biosciences by 395.6% during the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after acquiring an additional 117,588 shares in the last quarter. Finally, Armistice Capital LLC purchased a new stake in shares of Senti Biosciences during the second quarter worth $1,883,000. 25.70% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

SNTI has been the subject of several recent analyst reports. Wall Street Zen raised Senti Biosciences from a “strong sell” rating to a “hold” rating in a research report on Saturday, March 28th. Chardan Capital decreased their target price on Senti Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Monday, March 30th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Senti Biosciences in a research report on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $8.50.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.